10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

Commission File Number: 0-29901

Cavitation Technologies, Inc.

(Exact name of Registrant as Specified in its Charter)

Nevada	20-4907818
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA    91311

(Address, including Zip Code, of Principal Executive Offices )

(818) 718-0905

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.

YES    x       NO    ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     YES  x    NO  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer    ¨	Accelerated filer    ¨	Non-accelerated filer    ¨	Smaller reporting company    x
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES    ¨       NO    x

As of November 14, 2016, the issuer had 193,997,906 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
Part I.	FINANCIAL INFORMATION	1
Item 1.	Consolidated Financial Statements	1
	Condensed Consolidated Balance Sheets at September 30, 2016 (unaudited) and June 30, 2016	1
	Condensed Consolidated Statements of Operations - Three Months Ended September 30, 2016 (unaudited) and September 30, 2015 (unaudited)	2
	Condensed Consolidated Statement of Stockholders' Deficit - Three Months Ended September 30, 2016 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows - Three Months Ended September 30, 2016 (unaudited) and September 30, 2015 (unaudited)	4
	Notes to Condensed Consolidated Financial Statements (unaudited)	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Controls and Procedures	14
Part II.	OTHER INFORMATION	15
Item 1.	Legal Proceedings	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	16
Signatures		17

i

PART I - FINANCIAL INFORMATION

ITEM 1 - Condensed Consolidated Financial Statements

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,			June 30,
	2016			2016
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	443,037		$	657,396
Inventory, net		152,444			153,811
Total current assets		595,481			811,207
Property and equipment, net		114,232			122,641
Patents, net		12,978			16,336
Other assets		9,500			9,500
Total assets	$	732,191		$	959,684
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	154,042		$	171,029
Accrued payroll and payroll taxes due to officers		994,033			994,033
Related party payable		1,147			1,147
Advances from distributor, net		472,500			436,250
Total current liabilities		1,621,722			1,602,459
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2016 and June 30, 2016, respectively		-			-
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 193,997,906 shares issued and outstanding as of September 30, 2016 and June 30, 2016, respectively		193,998			193,998
Additional paid-in capital		22,062,888			22,062,888
Accumulated deficit		(23,146,417	)		(22,899,661	)
Total stockholders' deficit		(889,531	)		(642,775	)
Total liabilities and stockholders' deficit	$	732,191		$	959,684

See accompanying notes, which are an integral part of these condensed consolidated financial statements

1

CAVITATION TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	For the Three Months Ended
	September 30,
	2016			2015
Revenue	$	85,000		$	496,279
Cost of revenue		7,912			44,509
Gross profit		77,088			451,770
General and administrative expenses		317,515			288,653
Research and development expenses		6,329			12,508
Total operating expenses		323,844			301,161
Net Income (loss)	$	(246,756	)	$	150,609
Net income (loss) per share,
Basic and Diluted	$	(0.00	)	$	0.00
Weighted average shares outstanding,
Basic		193,997,906			193,997,906
Diluted		193,997,906			198,778,888

See accompanying notes, which are an integral part of these condensed consolidated financial statements

2

CAVITATION TECHNOLOGIES, INC.

Condensed Consolidated Statements of Changes in Stockholders' Deficit (unaudited)

	Series A Preferred				Common Stock				Additional Paid-		Accumalated
	Shares		Amount		Shares		Amount		in Capital		Deficit			Total
Balance at June 30, 2016		-	$	-		193,997,906	$	193,998	$	22,062,888		(22,899,661	)		(642,775	)
Net Loss												(246,756	)		(246,756	)
Balance at September 30, 2016		-	$	-		193,997,906	$	193,998	$	22,062,888	$	(23,146,417	)	$	(889,531	)

See accompanying notes, which are an integral part of these condensed consolidated financial statements

3

CAVITATION TECHNOLOGIES, INC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

	Three Months Ended September 30,
	2016			2015
Operating activities:
Net loss	$	(246,756	)	$	150,609
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		11,767			15,845
Effect of changes in:
Inventory		1,367			(10,879	)
Accounts payable and accrued expenses		(16,987	)		28,409
Advances from distributor		100,000			-
Reduction in advances due to realization of revenues from distributor		(63,750	)		(496,279	)
Net cash used in operating activities		(214,359	)		(312,295	)
Net change in cash		(214,359	)		(312,295	)
Cash, beginning of period		657,396			1,478,565
Cash, end of period	$	443,037		$	1,166,270
Supplemental disclosures of cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	1,600		$	1,600

See accompanying notes, which are an integral part of these condensed consolidated financial statements

4

CAVITATION TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Three months ended September 30, 2016 and 2015

Note 1 - Organization and Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending June 30, 2017. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2016 filed on October 13, 2016. The condensed consolidated balance sheet as of June 30, 2016 has been derived from the audited financial statements included in the Form 10-K for that year.

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patented Nano Reactor® is the critical component of CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, waste water treatment, biodiesel, algae oil extraction, and alcoholic beverage enhancement.

Management's Plan Regarding Going Concern

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.  During the three months ended September 30, 2016, the Company incurred a net loss of $246,756 and used $214,359 of cash in operating activities.  As of September 30, 2016, the Company had a working capital deficiency of $1,026,241 and a stockholders' deficit of $889,531. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. In addition, our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2016 expressed substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.

As of September 30, 2016, we had cash and cash equivalents on hand of $443,036 and are not generating sufficient funds to cover operations. In addition to the funds on hand, Management believes we will require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partner, the Desmet Ballestra Group (Desmet). Desmet has agreed to provide us monthly advances of $50,000 to be applied against future sales pursuant to a January 2016 agreement. During the three months ended September 30, 2016, the Company received $100,000 advances from Desmet.

We will also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

5

Note 2 - Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.

Fair Value Measurement

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

The three levels of the fair value hierarchy are as follows:

· Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

· Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

· Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

At September 30, 2016 and June 30, 2016, the fair values of cash and cash equivalents, inventory and accounts payable approximate their carrying values due to their short-term nature.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

Revenue Recognition

Revenue from the sale of our Nano Reactor® Systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured.

The Company is also entitled to certain non-refundable profit share from our distributor from the sale of the reactors. Pursuant to the January 2016 agreement with our distributor, the profit share is not fixed at the time of delivery, and as such, revenue will be recognized when the profit share is fixed and determinable, which will generally be upon delivery of the NANO Neutralization System by the distributor to its customer.

Patents

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other Than Goodwill. The Company has five patents issued in fiscal 2014, 2012 and 2011. During fiscal years 2015 and 2016, we also received approvals in the US for another 5 patents for various processes and 1 for another device/apparatus. We also received 1 patent approval for its device in Singapore. As of September 30, 2016, the Company has a total of 15 patents pending. The patents have duration of twenty years from filing date. The Company amortizes its patents over a four-year period which we believe is a reasonable estimate based upon its estimate of time until the next generation of reactors is developed or until other forms of competition appear.

6

During the three months ended September 30, 2016 and 2015, we recorded amortization expense of $3,358 and $6,021 respectively which was recorded as part of General and Administrative Expenses in the accompanying Statement of Operations. As of September 30, 2016, and June 30, 2016 the Company had remaining unamortized patent costs of $12,978 and $16,336 respectively.

Share-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Dependence on Desmet Ballestra

Our revenue is entirely dependent on Desmet Ballestra who is our exclusive distribution agent with regard to the CTi Nano Neutralization® System for edible oils. During the period ended September 30, 2016, 100% of our revenue was derived from Desmet sales efforts (see Note 3).

Basic Loss Per Share

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.

As of September 30, 2016, the Company had 11,685,852 stock options and 64,326,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on our ongoing financial reporting.

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures.

7

In March 2016, the FASB issued the ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this ASU require, among other things, that all income tax effects of awards be recognized in the income statement when the awards vest or are settled. The ASU also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Business and Credit Concentrations

The Company’s cash balances in financial institutions at times may exceed federally insured limits. As of September 30, 2016, and June 30, 2016, before adjustments for outstanding checks and deposits in transit, the Company had approximately $443,000 and $657,000, respectively, deposited in one financial institution. The deposits are federally insured up to $250,000. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

All recorded revenues during the three months ended September 30, 2016 of $85,000 were attributable to one customer (see Note 3).

Note 3 - Agreement with Desmet Ballestra

On January 22, 2016, the Company signed a three-year agreement with Desmet effective August 1, 2015 for the sale and marketing of the Company’s Nano reactor system. As part of the agreement, Desmet will provide, under certain conditions, limited monthly advance payments of $50,000 against future sales to CTi. The agreement may be terminated by Desmet every August 1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors System to sold status during the period of June 1 to May 31. The agreement may also be terminated in case the Company loses ownership of patents and patent applications being used in the NANO Neutralization System.

Pursuant to the 2016 Agreement, the Company recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet other than the reactor’s two-year standard warranty. In addition, Desmet now pays for such reactors on credit terms and the amount of the sale is recorded as a receivable upon acceptance by Desmet. The Company also continues to receive a share in gross margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an integral component, however, such amount is now subject to adjustment based on certain factors including costs over run. The Company deemed that such amount is not yet fixed and determinable upon shipment of the reactors. As a result, the corresponding revenue is now being recognized upon installation and acceptance of the integrated neutralization system by Desmet’s customer.

During the three months ended September 30, 2016, the Company recognized revenue of $85,000 related to the shipment and acceptance of reactors to Desmet and received advances in the aggregate of $100,000 pursuant to this agreement. As of September 30, 2016, the Company also recorded receivable from Desmet in the aggregate of $127,500, as such, for financial reporting purposes, the Company deducted this amount from the advance payments received which resulted in a net balance of $472,500 in advances from distributor, net as of that date. The Company expects to recognize approximately $317,000 from its share in gross margin in future periods upon delivery and acceptance of the NANO Neutralization System by Desmet to its customer.

8

Note 4 - Property and Equipment

Property and equipment consisted of the following as of September 30, 2016 and June 30, 2016:

	September 30,			June 30,
	2016			2016
Leasehold  improvement	$	2,475		$	2,475
Furniture		26,837			26,837
Office equipment		1,499			1,499
Equipment		68,380			68,380
Systems		352,655			352,655
		451,846			451,846
Less: accumulated depreciation and amortization		(337,614	)		(329,205	)
Property & Equipment, net	$	114,232		$	122,641

Depreciation expense for the three months ended September 30, 2016 and 2015 amounted to $8,409 and $9,824, respectively which was recorded as part of General and Administrative Expenses in the accompanying Statement of Operations.

Note 5 - Accrued Payroll and Payroll Taxes

As of September 30, 2016 and June 30, 2016, the Company had accrued unpaid salaries due to current and former officers of the Company and the corresponding estimated payroll taxes in the aggregate of $994,033.

Note 6 - Stockholders' Deficit

Stock Options

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity from September 30, 2016 is as follows:

						Weighted-
						Average
				Weighted-		Remaining
				Average		Contractual
				Exercise		Life
	Options			Price		(Years)
Outstanding June 30, 2016		12,595,992		$	0.10		4.96
- Granted		-
- Forfeited		-			-		-
- Exercised		-			-		-
- Expired		(910,140	)		-		-
Outstanding September 30, 2016		11,685,852		$	0.07		5.02
Exercisable and vested at September 30, 2016		11,685,852		$	0.07		5.02

The intrinsic value of the outstanding options was $0 as of September 30, 2016.

The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2016.

9

		Options Outstanding						Options Exercisable
				Weighted		Weighted				Weighted
				Average		Average				Average
Exercise		Number		Remaining		Exercise		Number		Remaining
Price		of Shares		Life (Years)		Price		of Shares		Life (Years)
$	0.03		11,000,000		5.71	$	0.03		11,000,000		5.71
$	0.33		174,022		1.85	$	0.33		174,022		1.85
$	0.67		511,830		1.75	$	0.67		511,830		1.75
			11,685,852						11,685,852

Warrants

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2016 is as follows.

					Weighted-
					Average
			Weighted-		Remaining
			Average		Contractual
			Exercise		Life
	Warrants		Price		(Years)
Outstanding at June 30, 2016		64,326,510	$	0.07		5.09
Granted		-	$	-		-
Exercised		-	$	-
Expired		-	$	-
Outstanding at September 30, 2016		64,326,510	$	0.07		4.83
Vested and exercisable at September 30, 2016		64,326,510	$	0.07		4.83

As of September 30, 2016, all warrants granted were vested. The intrinsic value of the outstanding warrants was $0 as of September 30, 2016. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2016.

		Warrants Outstanding						Warrants Exercisable
				Weighted		Weighted				Weighted
				Average		Average				Average
Exercise		Number		Remaining		Exercise		Number		Exercise
Price		of Shares		Life (Years)		Price		of Shares		Price
$	0.04 - 0.07		43,999,851		5.69	$	0.05		43,999,851	$	0.05
$	0.12		20,326,659		3.00	$	0.12		20,326,659	$	0.12
			64,326,510						64,326,510

10

Note 7 - Commitments and Contingencies

Litigation

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies (commencing April 1, 2009), the Company records accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.

In August 2014, a former employee and former Director filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties and interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of the Company and dismissed the case. As a result of this ruling, the Company’s obligation to the former employee and former Director only amounted to approximately $134,000 which was already accrued in prior periods and included as part of Accrued Payroll and payroll taxes due to officers in the accompanying balance sheet.

In February 2016, the former employee and former Director appealed this ruling to the Los Angeles County Superior Court.  In addition to defending itself, the Company also has filed a cross-complaint against the former employee and former Director for breach of contract and breach of fiduciary duty as a Director.  Trial is currently scheduled to begin in 2017. Based upon available information at this very early stage of litigation, Management believes the likelihood of material loss resulting from this lawsuit to be remote.

11

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

Overview of our Business

Cavitation Technologies, Inc. ("CTi"), a Nevada corporation, was originally incorporated under the name Bio Energy, Inc. We design and engineer environmentally friendly technology based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, algae oil extraction, biodiesel production, water-oil emulsions and crude oil yield enhancement.  Our systems are designed to process industrial liquids at a lower cost and higher yield than conventional technology. We are a process and product development firm that has developed, patented, and commercialized proprietary technology.

CTi has developed, patented, and commercialized proprietary technology that can be used for processing of industrial fluids. CTi's patented Nano Reactor® is the critical components of the CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in processing oils and fats. CTi has two issued patents relating to our Nano Reactor® systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, biodiesel production, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

During the three months ended September 30, 2016, we recorded revenue of $85,000, net loss of $246,756 and used cash in operations of $214,359.

Management's Plan

We are engaged in merchandising our Neutralization System which is designed to help refine vegetable oils such as soybean, canola, sunflower and rapeseed.  Our near term goal is to continue to merchandise our systems through our partner, Desmet Ballestra Group (Desmet). During the three months ended September 30, 2016, we recorded revenues of $85,000 and incurred a net loss of $246,756.  As of September 30, 2016, the Company had a working capital deficiency of $1,026,241 and a stockholders' deficit of $889,531.   The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.

As of September 30, 2016, we had cash and cash equivalents on hand of $443,037 and are not generating sufficient funds to cover operations. In addition to the funds on hand, Management believes we will require additional funds to continue to operate our business. Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partner, Desmet. Desmet has agreed to provide us monthly advances of $50,000 to be applied against future sales pursuant to a January of 2016 agreement. During the three months ended September 30, 2016, the Company received $100,000 advances from Desmet.

In addition to these advances, we anticipate that we will need additional funding, and we will attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such agreement with Desmet will be successful and such financing will be consummated or obtained in sufficient amounts necessary to meet our needs, or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we may curtail operations. The accompanying condensed consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. As a result of the aforementioned factors, our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2016, expressed substantial doubt about our ability to continue as a going concern.

Critical Accounting Policies

CTi's critical accounting policies and estimates are included in its Annual Report on Form 10-K for the year ended June 30, 2016, and did not change for the three months ended September 30, 2016.

12

 Results of Operations

The following is a comparison of our results of operations for the three months ended September 30, 2016 and 2015.

	For the Quarter Ended
	Sept 30,
	2016			2015		$ Change			% Change
Revenue	$	85,000		$	496,279	$	(411,279	)		-82.9	%
Cost of revenue		7,912			44,509		(36,597	)		-82.2	%
Gross profit		77,088			451,770		(374,682	)		-82.9	%
General and administrative expenses		317,515			288,653		28,862			10.0	%
Research and development expenses		6,329			12,508		(6,179	)		-49.4	%
Total operating expenses		323,844			301,161		22,683			7.5	%
Income (loss) from operations		(246,756	)		150,609		(397,365	)		-263.8	%
Interest expense and other		-			-		-
Net income (loss)	$	(246,756	)	$	150,609		(397,365	)		-263.8	%

Revenue

We recorded $85,000 in revenue in the first three months September 30, 2016 and $496,279 in revenue in the three months ended September 30, 2015. Included in the recorded revenue for the three-month ended September 30, 2015 was a share in gross margin from the sale of reactor system to Desmet amounting to $341,278. There was no similar transaction recorded in 2016.

Cost of Revenue

During the three months ended September 30, 2016, our cost of sales amounted to $7,912, and to $44,509 during the same period in prior year, which was the result of the revenue transactions described above.

Operating Expenses

Operating expenses for the three months ended September 30, 2017 amounted to $323,844 compared with $301,161 for the same period in 2016, an increase of $22,683, or 7.5%. In the first quarter of fiscal 2017, compensation amounted to $137,689 or 43% of total costs compared with $104,228 or 35% of total costs in the first quarter of fiscal 2016. This increase in compensation in the first quarter of fiscal 2017 was attributable largely to an increase in management salaries.

The other major component of operating expense was professional service fees related to accounting, and legal services which amounted to $56,507 or 17% of total operating expenses versus professional service fees related to accounting, and legal services which amounted to $47,318 or 16% in fiscal 2016.

Research and development (R&D) expenses remained relatively low as we continued to rely on Desmet Ballestra for support in R&D. It is our intention to pursue R&D as our cash position permits.

13

Liquidity and Capital Resources

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.   As of September 30, 2016, the Company had a working capital deficiency of $1,026,241 and a stockholders' deficit of $889,531. Furthermore, we have been dependent on most of our funding from a technology agreement with a distributor. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2016 expressed substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of us to continue as a going concern.

Management's plan is to generate income from operations by licensing our technology globally through our strategic partner, the Desmet Ballestra Group (Desmet). In January 2016, we signed a marketing and research and development agreement with Desmet which include among others, a monthly advance of $50,000 that will be applied to future sales. We will need additional funding, and we will attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

At September 30, 2016, we had cash on hand in the amount of $443,037. In addition to the funds on hand, we will require additional funds to continue to operate our business. This includes expenses we will incur in connection with costs to manufacture and ship our products; costs to design and implement an effective system of internal controls and disclosure controls and procedures; costs of maintaining our status as a public company by filing periodic reports with the SEC and costs required to protect our intellectual property. In addition, we have contractual commitments for salaries to our executive officers. In light of our financial commitments over the next several months and its liquidity constraints, we have implemented cost reduction measures in all areas of operations. We intend to review these measures on an ongoing basis and make additional decisions as may be required.

Cash Flow

Net cash used by operating activities during the three months ended September 30, 2016 amounted to $214,359 compared with $312,295 provided by these activities for the same period in fiscal 2016. Funding for the operating activities was provided by cash reserves and advances from a distributor. For the first quarter of fiscal 2017, we paid $137,639 in employees' compensation, $56,507 in professional services fees, $24,766 in various insurance premiums, and approximately $100,000 in fixed operating costs and other obligations. In the first quarter of 2016, we paid $104,228 in employees' compensation, $47,318 in professional services fees, $24,500 in various insurance premiums, and approximately $137,000 in fixed operating costs and other obligations.

There was no cash used for investing activities in the current fiscal quarter, as well as the same period of fiscal 2016.

For the periods ended September 30, 2016, and September 30, 2015 there were no financing activities.

ITEM 3.  Quantitative and Qualitative Disclosures about Market Risk.

Not applicable for smaller reporting companies.

ITEM 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In accordance with rule 13a-15(a), CTi management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In accordance with Rule 13a-15(b) and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of September 30, 2016, the Company carried out an evaluation, under the supervision and with the participation of its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Company's principal executive officer and principal financial officer concluded that these disclosure controls and procedures were not effective as of September 30, 2016.

14

Changes in Internal Control over Financial Reporting

There were no changes in internal control over financial reporting during the first quarter of fiscal 2016 that have materially affected or are reasonably likely to materially affect the company's internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1  Legal Proceedings

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 2  Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 - Defaults Upon Senior Securities

None

Item 4 - Mine Safety Disclosures

None

Item 5 - Other Information

None

15

Item 6 - EXHIBITS, FINANCIAL STATEMENT SCHEDULES

			Incorporated by Reference
Exhibit		Filed
Number	Exhibit Description	Herewith	Form	Pd. Ending	Exhibit	Filing Date
3(i)(a)	Articles of Incorporation - original name of Bioenergy, Inc.		SB-2	N/A	3.1	October 19, 2006
3(i)(b)	Articles of Incorporation - Amended and Restated		10-Q	December 31, 2008	3-1	February 17, 2009
3(i)( c )	Articles of Incorporation - Amended and Restated		10-Q	June 30, 2009	3-1	May 14, 2009
3(i)(d)	Articles of Incorporation - Amended; increase in authorized shares		8-K	N/A	N/A	October 29, 2009
3(i)(e)	Articles of Incorporation - Certificate of Amendment; forward split		10-Q	December 31, 2009	3-1	November 16, 2009
10.1	Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.		8-K	June 30, 2009	10.1	May 18, 2010
10.2	Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.		8-K	June 30, 2009	10.2	May 18, 2010
10.3	Assignment of Patent Assignment Agreement between the Company and Roman Gordon		8-K	June 30, 2009	10.3	May 18, 2010
10.4	Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky		8-K	June 30, 2009	10.4	May 18, 2010
10.5	Employment Agreement between the Company and Roman Gordon date March 17, 2008		10K/A	June 30, 2009	10.3	October 20, 2011
10.6	Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008		10K/A	June 30, 2009	10.4	October 20, 2011
10.7	Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008		10-Q	December 31, 2010	10.3	February 11, 2011
10.8	Board of Director Agreement - James Fuller		10-Q	December 31, 2011	10.12	October 20, 2011
10.9	Technology and License Agreement with Desmet Ballestra dated 14 May 2012		10-K	June 30, 2012	10.1	October 15, 2012
10.10	Short Term Loan Agreement - CEO		10-K	June 30, 2012	10.11	October 15, 2012
14.1	Code of Business Conduct and Ethics*		10-K	June 30, 2011	14.1	September 28, 2011
31.1	Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002	X
31.2	Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002	X
32.1	Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted	X
	pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted	X
	pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document	X
101.SCH	XBRL Taxonomy Extension Schema	X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
101.DEF	XBRL Taxonomy Extension Definition Linkbase	X
101.LAB	XBRL Taxonomy Extension Label Linkbase	X
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
*	In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person
	without charge, upon request, a copy of our "Code of Business Conduct and Ethics". A copy may be requested
	by sending an email to info@cavitationtechnologies.com.

16

SIGNATURES

Pursuant to the requirements of the securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURE	TITLE	DATE
/s/ Igor Gorodnitsky	President; Member of Board of Directors	November 14, 2016
6Igor Gorodnitsky	(Principal Executive Officer)
/s/ N. Voloshin	Chief Financial Officer	November 14, 2016
N. Voloshin	(Principal Financial Officer)
/s/ Jim Fuller	Audit Committee Chairman, Independent Financial Expert	November 14, 2016
Jim Fuller

17

EX-31.1

Exhibit 31.1

Certification

I, Igor Gorodnitsky, certify that:

1. I have reviewed this quarterly report for the period ending September 30, 2016 on Form 10-Q of Cavitation Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016	/s/ IGOR GORODNITSKY
	Name: Igor Gorodnitsky Title: Principal Executive Officer

EX-31.2

Exhibit 31.2

Certification

I, N. Voloshin, certify that:

1. I have reviewed this quarterly report for the period ending September 30, 2016 on Form 10-Q of Cavitation Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as

defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016	/s/ N. VOLOSHIN
	Name: N. Voloshin Title: Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION

I, Igor Gorodnitsky, Principal Executive Officer of Cavitation Technologies, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2016	/s/ IGOR GORODNITSKY
	Name: Igor Gorodnitsky Title: Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION

I, N. Voloshin, Chief Financial Officer of Cavitation Technologies, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

The Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2016	/s/ N. VOLOSHIN
	Name: N. Voloshin Title: Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Nov. 14, 2016
Document and Entity Information:
Entity Registrant Name	Cavitation Technologies, Inc.
Entity Trading Symbol	cvat
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Entity Central Index Key	0001376793
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		193,997,906
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 443,037	$ 657,396
Inventory, net	152,444	153,811
Total current assets	595,481	811,207
Property and equipment, net	114,232	122,641
Patents, net	12,978	16,336
Other assets	9,500	9,500
Total assets	732,191	959,684
Current liabilities:
Accounts payable and accrued expenses	154,042	171,029
Accrued payroll and payroll taxes due to officers	994,033	994,033
Related party payable	1,147	1,147
Advances from distributor, net	472,500	436,250
Total current liabilities	1,621,722	1,602,459
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2016 and June 30, 2016, respectively	0	0
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 193,997,906 shares issued and outstanding as of September 30, 2016 and June 30, 2016, respectively	193,998	193,998
Additional paid-in capital	22,062,888	22,062,888
Accumulated deficit	(23,146,417)	(22,899,661)
Total stockholders' deficit	(889,531)	(642,775)
Total liabilities and stockholders' deficit	$ 732,191	$ 959,684

XML

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS - $ / shares	Sep. 30, 2016	Jun. 30, 2016
Parentheticals
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, shares issued	193,997,906	193,997,906
Common Stock, shares outstanding	193,997,906	193,997,906

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenues {1}
Revenue	$ 85,000	$ 496,279
Cost of revenue	7,912	44,509
Gross profit	77,088	451,770
General and administrative expenses	317,515	288,653
Research and development expenses	6,329	12,508
Total operating expenses	323,844	301,161
Net Income (loss)	$ (246,756)	$ 150,609
Net income (loss) per share, Basic and Diluted	$ 0.00	$ 0.00
Weighted average shares outstanding,
Basic	193,997,906	193,997,906
Diluted	193,997,906	198,778,888

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER'S DEFICIT (unaudited) - 3 months ended Sep. 30, 2016 - USD ($)	Preferred Shares Amount	Common Stock Shares	Common Stock Amount	Additional Paid- in Capital	Accumalated Deficit	Total
Balance at Jun. 30, 2016		193,997,906	193,995	22,062,883	(22,899,661)	(642,775)
Changes in Stockholders Deficit
Net Loss	$ 0				$ (246,756)	$ (246,756)
Balance at Sep. 30, 2016		193,997,906	193,993	1,061,883	(23,146,417)	(889,531)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (246,756)	$ 150,609
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,767	15,845
Effect of changes in:
Inventory	1,367	(10,879)
Accounts payable and accrued expenses	(16,987)	28,409
Advances from distributor	100,000	0
Reduction in advances due to realization of revenues from distributor	(63,750)	(496,279)
Net cash used in operating activities	(214,359)	(312,295)
Net change in cash	(214,359)	(312,295)
Cash, beginning of period	657,396	1,478,565
Cash, end of period	443,037	1,166,270
Supplemental disclosures of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	$ 1,600	$ 1,600

XML

Organization and Basis of Presentation

3 Months Ended

Sep. 30, 2016

Organization and Basis of Presentation

Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.") and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended (the "Exchange Act") and Article 8-03 of Regulation S-X under the Exchange Act. Accordingly, these condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended September 30, 2016 are not indicative of the results that may be expected for the fiscal year ending June 30, 2017. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended June 30, 2016 filed on October 13, 2016. The condensed consolidated balance sheet as of June 30, 2016 has been derived from the audited financial statements included in the Form 10-K for that year.

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") is a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patented Nano Reactor® is the critical component of CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, waste water treatment, biodiesel, algae oil extraction, and alcoholic beverage enhancement.

Management's Plan Regarding Going Concern

The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.  During the three months ended September 30, 2016, the Company incurred a net loss of $246,756 and used $214,359 of cash in operating activities.  As of September 30, 2016, the Company had a working capital deficiency of $1,026,241 and a stockholders' deficit of $889,531. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. In addition, our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2016 expressed substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.

As of September 30, 2016, we had cash and cash equivalents on hand of $443,036 and are not generating sufficient funds to cover operations.  In addition to the funds on hand, Management believes we will require additional funds to continue to operate our business.  Management's plan is to generate income from operations by continuing to license our technology globally through our strategic partner, the Desmet Ballestra Group (Desmet). Desmet has agreed to provide us monthly advances of $50,000 to be applied against future sales pursuant to a January 2016 agreement. During the three months ended September 30, 2016, the Company received $100,000 advances from Desmet.

We will also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

XML

Significant Accounting Policies

3 Months Ended

Sep. 30, 2016

Significant Accounting Policies:

Significant Accounting Policies

Note 2 - Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Inter-company transactions and balances have been eliminated in consolidation.

Fair Value Measurement

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

The three levels of the fair value hierarchy are as follows:

• Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
• Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
• Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

At September 30, 2016 and June 30, 2016, the fair values of cash and cash equivalents, inventory and accounts payable approximate their carrying values due to their short-term nature.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

Revenue Recognition

Revenue from the sale of our Nano Reactor® Systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured.

The Company is also entitled to certain non-refundable profit share from our distributor from the sale of the reactors.  Pursuant to the January 2016 agreement with our distributor, the profit share is not fixed at the time of delivery, and as such, revenue will be recognized when the profit share is fixed and determinable, which will generally be upon delivery of the NANO Neutralization System by the distributor to its customer.

Patents

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other Than Goodwill. The Company has five patents issued in fiscal 2014, 2012 and 2011. During fiscal years 2015 and 2016, we also received approvals in the US for another 5 patents for various processes and 1 for another device/apparatus. We also received 1 patent approval for its device in Singapore.  As of September 30, 2016, the Company has a total of 15 patents pending. The patents have duration of twenty years from filing date. The Company amortizes its patents over a four-year period which we believe is a reasonable estimate based upon its estimate of time until the next generation of reactors is developed or until other forms of competition appear.

During the three months ended September 30, 2016 and 2015, we recorded amortization expense of $3,358 and $6,021 respectively which was recorded as part of General and Administrative Expenses in the accompanying Statement of Operations.  As of September 30, 2016, and June 30, 2016 the Company had remaining unamortized patent costs of $12,978 and $16,336 respectively.

Share-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Dependence on Desmet Ballestra

Our revenue is entirely dependent on Desmet Ballestra who is our exclusive distribution agent with regard to the CTi Nano Neutralization® System for edible oils.  During the period ended September 30, 2016, 100% of our revenue was derived from Desmet sales efforts (see Note 3).

Basic Loss Per Share

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.

As of September 30, 2016, the Company had 11,685,852 stock options and 64,326,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on our ongoing financial reporting.

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases.  ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months.  ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018.  Early adoption is permitted.  A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.  The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures.

In March 2016, the FASB issued the ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this ASU require, among other things, that all income tax effects of awards be recognized in the income statement when the awards vest or are settled. The ASU also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Business and Credit Concentrations

The Company’s cash balances in financial institutions at times may exceed federally insured limits. As of September 30, 2016, and June 30, 2016, before adjustments for outstanding checks and deposits in transit, the Company had approximately $443,000 and $657,000, respectively, deposited in one financial institution. The deposits are federally insured up to $250,000. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

All recorded revenues during the three months ended September 30, 2016 of $85,000 were attributable to one customer (see Note 3). 

XML

Agreement with Desmet Ballestra and Revenue Recognition

3 Months Ended

Sep. 30, 2016

Agreement with Desmet Ballestra and Revenue Recognition

Agreement with Desmet Ballestra and Revenue Recognition

Note 3 - Agreement with Desmet Ballestra

On January 22, 2016, the Company signed a three-year agreement with Desmet effective August 1, 2015 for the sale and marketing of the Company’s Nano reactor system.  As part of the agreement, Desmet will provide, under certain conditions, limited monthly advance payments of $50,000 against future sales to CTi.  The agreement may be terminated by Desmet every August 1 should Desmet and its affiliates fail to convert a minimum of six Nano Reactors System to sold status during the period of June 1 to May 31.  The agreement may also be terminated in case the Company loses ownership of patents and patent applications being used in the NANO Neutralization System.

Pursuant to the 2016 Agreement, the Company recognizes revenue from sale of reactors upon shipment and acceptance by Desmet, as the Company has no further obligations to Desmet other than the reactor’s two-year standard warranty. In addition, Desmet now pays for such reactors on credit terms and the amount of the sale is recorded as a receivable upon acceptance by Desmet.  The Company also continues to receive a share in gross margin or profit from the sale of Desmet’s integrated neutralization system to its customer of which the reactors are an integral component, however, such amount is now subject to adjustment based on certain factors including costs over run.  The Company deemed that such amount is not yet fixed and determinable upon shipment of the reactors.  As a result, the corresponding revenue is now being recognized upon installation and acceptance of the integrated neutralization system by Desmet’s customer. 

During the three months ended September 30, 2016, the Company recognized revenue of $85,000 related to the shipment and acceptance of reactors to Desmet and received advances in the aggregate of $100,000 pursuant to this agreement.  As of September 30, 2016, the Company also recorded receivable from Desmet in the aggregate of $127,500, as such, for financial reporting purposes, the Company deducted this amount from the advance payments received which resulted in a net balance of $472,500 in advances from distributor, net as of that date.  The Company expects to recognize approximately $317,000 from its share in gross margin in future periods upon delivery and acceptance of the NANO Neutralization System by Desmet to its customer.

XML

Property and Equipment

3 Months Ended

Sep. 30, 2016

Property and Equipment

Property and Equipment

Note 4 - Property and Equipment

Property and equipment consisted of the following as of September 30, 2016 and June 30, 2016:

	September 30,2016		June 30,2016
Leasehold improvement	$	2,475	$	2,475
Furniture		26,837		26,837
Office equipment		1,499		1,499
Equipment		68,380		68,380
Systems		352,655		352,655
		451,846		451,846
Less: accumulated depreciation and amortization		(337,614)		(329,205)
Property & Equipment, net	$	114,232	$	122,641

XML

Accrued Payroll and Payroll Taxes

3 Months Ended

Sep. 30, 2016

Accrued Payroll and Payroll Taxes

Accrued Payroll and Payroll Taxes

Note 5 - Accrued Payroll and Payroll Taxes

As of September 30, 2016 and June 30, 2016, the Company had accrued unpaid salaries due to current and former officers of the Company and the corresponding estimated payroll taxes in the aggregate of $994,033.

XML

Stockholders' Deficit

3 Months Ended

Sep. 30, 2016

Stockholders' Deficit

Stockholders' Deficit

Note 6 - Stockholders' Deficit

Stock Options

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non- plan grants. A summary of the stock option activity from September 30, 2016 is as follows:

	Options	Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Life(Years)
Outstanding June 30, 2016	12,595,992	$	0.10	4.96
- Granted	-		-	-
- Forfeited	-		-	-
- Exercised	-		-	-
- Expired	(910,140)		-	-
Outstanding September 30, 2016	11,685,352	&	0.07	5.02
Exercisable and vested at September 30, 2016	11,635,352	&	0.07	5.02

The intrinsic value of the outstanding options was $0 as of September 30, 2016.

The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2016.

			Options Outstanding		Options Exercisable
Exercise Price	Number of Shares		Weighted Average Remaining Life (Years)	Weighted Average Exercise	Number of Shares	Weighted Average Remaining Life (Years)
$0.03	11,000,000	5.71		$0.03	11,000,000	5.71
$                   0.33	174,022	1.85		$0.33	174,022	1.85
$0.67	511,830	1.75		$0.67	511,830	1.75
	11,685,852				11,685,852

Warrants

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2016 is as follows.

			Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (Years)
	Warrants
Outstanding at June 30, 2016	64,326,510	$	0.07	5.09
Granted	-	$	-	-
Exercised	-	$	-
Expired	-	$	-
Outstanding at September 30, 2016	64,326,510	$	0.07	4.83
Vested and exercisable at September 30. 2016	64,326,510	$	0.07	4.83

As of September 30, 2016, all warrants granted were vested. The intrinsic value of the outstanding warrants was $0 as of September 30, 2016. The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2016.

				Warrants Outstanding		Warrants Exercisable
Exercise Price		Number of Shares		Weighted Average Remaining Life (Years)	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price)
$	0.04 - 0.07	43,999,851		5.69	$            0.05	43,999,851	$	0.05
$	0.12	20,326,659	3.00		$            0.12	20,326,659	$	0.12
		64,326,510				64,326,510

XML

Commitment and Contingencies

3 Months Ended

Sep. 30, 2016

Commitment and Contingencies:

Commitments and Contingencies Disclosure

Note 7 - Commitments and Contingencies

Litigation

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies (commencing April 1, 2009), the Company records accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.

In August 2014, a former employee and former Director filed an administrative Complaint for approximately $179,000 in unpaid wages, plus penalties and interest, with the California Labor Commissioner’s Office (CLCO).  In January 2016, the CLCO ruled in favor of the Company and dismissed the case. As a result of this ruling, the Company’s obligation to the former employee and former Director only amounted to approximately $134,000 which was already accrued in prior periods and included as part of Accrued Payroll and payroll taxes due to officers in the accompanying balance sheet.

In February 2016, the former employee and former Director appealed this ruling to the Los Angeles County Superior Court.  In addition to defending itself, the Company also has filed a cross-complaint against the former employee and former Director for breach of contract and breach of fiduciary duty as a Director.  Trial is currently scheduled to begin in 2017. Based upon available information at this very early stage of litigation, Management believes the likelihood of material loss resulting from this lawsuit to be remote.

XML

Accounting Policies (Policies)

3 Months Ended

Sep. 30, 2016

Accounting Policies (Policies):

Principles of Consolidation , Policy

Business and Credit Concentrations

The Company’s cash balances in financial institutions at times may exceed federally insured limits. As of September 30, 2016, and June 30, 2016, before adjustments for outstanding checks and deposits in transit, the Company had approximately $443,000 and $657,000, respectively, deposited in one financial institution. The deposits are federally insured up to $250,000. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

All recorded revenues during the three months ended September 30, 2016 of $85,000 were attributable to one customer (see Note 3).

Fair Value Measurement, Policy

Fair Value Measurement

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

The three levels of the fair value hierarchy are as follows:

• Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
• Level 2 - Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
• Level 3 - Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

At September 30, 2016 and June 30, 2016, the fair values of cash and cash equivalents, inventory and accounts payable approximate their carrying values due to their short-term nature.

Use of Estimates, Policy

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for fixed assets, accrual of potential liabilities and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.

Revenue Recognition , Policy

Revenue Recognition

Revenue from the sale of our Nano Reactor® Systems is recognized when persuasive evidence of an agreement exists; shipment has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured.

The Company is also entitled to certain non-refundable profit share from our distributor from the sale of the reactors.  Pursuant to the January 2016 agreement with our distributor, the profit share is not fixed at the time of delivery, and as such, revenue will be recognized when the profit share is fixed and determinable, which will generally be upon delivery of the NANO Neutralization System by the distributor to its customer.

Patents, Policy

Patents

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other Than Goodwill. The Company has five patents issued in fiscal 2014, 2012 and 2011. During fiscal years 2015 and 2016, we also received approvals in the US for another 5 patents for various processes and 1 for another device/apparatus. We also received 1 patent approval for its device in Singapore.  As of September 30, 2016, the Company has a total of 15 patents pending. The patents have duration of twenty years from filing date. The Company amortizes its patents over a four-year period which we believe is a reasonable estimate based upon its estimate of time until the next generation of reactors is developed or until other forms of competition appear.

During the three months ended September 30, 2016 and 2015, we recorded amortization expense of $3,358 and $6,021 respectively which was recorded as part of General and Administrative Expenses in the accompanying Statement of Operations.  As of September 30, 2016, and June 30, 2016 the Company had remaining unamortized patent costs of $12,978 and $16,336 respectively.

Share-Based Compensation Policy

Share-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The fair value of the Company's common stock options and warrants grant is estimated using the Black-Scholes option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Dependence on Desmet Ballestra , Policy

Dependence on Desmet Ballestra

Our revenue is entirely dependent on Desmet Ballestra who is our exclusive distribution agent with regard to the CTi Nano Neutralization® System for edible oils.  During the period ended September 30, 2016, 100% of our revenue was derived from Desmet sales efforts (see Note 3).

Basic Loss Per Share

Basic Loss Per Share

The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price and there were no instruments that would result in issuance of additional shares during the period.

As of September 30, 2016, the Company had 11,685,852 stock options and 64,326,510 stock warrants outstanding to purchase shares of common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.

Recent Accounting Pronouncements , Policy

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 and has not determined the effect of the standard on our ongoing financial reporting.

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases.  ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months.  ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018.  Early adoption is permitted.  A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available.  The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures.

In March 2016, the FASB issued the ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this ASU require, among other things, that all income tax effects of awards be recognized in the income statement when the awards vest or are settled. The ASU also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Business and Credit Concentrations, Policy

Business and Credit Concentrations

The Company’s cash balances in financial institutions at times may exceed federally insured limits. As of September 30, 2016, and June 30, 2016, before adjustments for outstanding checks and deposits in transit, the Company had approximately $443,000 and $657,000, respectively, deposited in one financial institution. The deposits are federally insured up to $250,000. The Company believes that no significant concentration of credit risk exists with respect to these cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

All recorded revenues during the three months ended September 30, 2016 of $85,000 were attributable to one customer (see Note 3). 

XML

Schedule Of Property and Equipment (Tables)

3 Months Ended

Sep. 30, 2016

Schedule Of Property and Equipment (Tables):

Schedule Of Property and Equipment (Tables)

Property and equipment consisted of the following as of September 30, 2016 and June 30, 2016:

	September 30,2016		June 30,2016
Leasehold improvement	$	2,475	$	2,475
Furniture		26,837		26,837
Office equipment		1,499		1,499
Equipment		68,380		68,380
Systems		352,655		352,655
		451,846		451,846
Less: accumulated depreciation and amortization		(337,614)		(329,205)
Property & Equipment, net	$	114,232	$	122,641

XML

Schedule Of Stock Option Activity (Tables)

3 Months Ended

Sep. 30, 2016

Schedule Of Stock Option Activity (Tables):

Schedule Of Stock Option Activity (Tables)

A summary of the stock option activity from September 30, 2016 is as follows:

	Options	Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Life(Years)
Outstanding June 30, 2016	12,595,992	$	0.10	4.96
- Granted	-		-	-
- Forfeited	-		-	-
- Exercised	-		-	-
- Expired	(910,140)		-	-
Outstanding September 30, 2016	11,685,352	&	0.07	5.02
Exercisable and vested at September 30, 2016	11,635,352	&	0.07	5.02

Schedule Of Options Outstanding And Exercisable (Tables)

The following table summarizes additional information concerning options outstanding and exercisable at September 30, 2016.

			Options Outstanding		Options Exercisable
Exercise Price	Number of Shares		Weighted Average Remaining Life (Years)	Weighted Average Exercise	Number of Shares	Weighted Average Remaining Life (Years)
$0.03	11,000,000	5.71		$0.03	11,000,000	5.71
$                   0.33	174,022	1.85		$0.33	174,022	1.85
$0.67	511,830	1.75		$0.67	511,830	1.75
	11,685,852				11,685,852

XML

Schedule Of Warrants Activity (Tables)

3 Months Ended

Sep. 30, 2016

Schedule Of Warrants Activity (Tables):

Schedule Of Warrants Activity (Tables)

A summary of the Company's warrant activity and related information for the three months ended on September 30, 2016 is as follows.

			Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (Years)
	Warrants
Outstanding at June 30, 2016	64,326,510	$	0.07	5.09
Granted	-	$	-	-
Exercised	-	$	-
Expired	-	$	-
Outstanding at September 30, 2016	64,326,510	$	0.07	4.83
Vested and exercisable at September 30. 2016	64,326,510	$	0.07	4.83

Schedule Of Warrants Outstanding And Exercisable (Tables)

The following table summarizes additional information concerning warrants outstanding and exercisable at September 30, 2016.

				Warrants Outstanding		Warrants Exercisable
Exercise Price		Number of Shares		Weighted Average Remaining Life (Years)	Weighted Average Exercise Price	Number of Shares	Weighted Average Exercise Price)
$	0.04 - 0.07	43,999,851		5.69	$            0.05	43,999,851	$	0.05
$	0.12	20,326,659	3.00		$            0.12	20,326,659	$	0.12
		64,326,510				64,326,510

XML

Going Concern (Narrative) (Details)	3 Months Ended
	Sep. 30, 2016 USD ($)
Going Concern Narrative Details
Working capital deficiency	$ 1,026,241
Total stockholders' deficit	889,531
Cash and cash equivalents on hand	443,036
Minimum monthly advances from Desmet	50,000
Received Advances from Desmet	100,000
Cash in operations	$ 214,359

XML

Significant Accounting policies-Patents (Details) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Significant Accounting policies-Patents Details
Patent amortization expense	$ 3,358	$ 6,021
Remaining unamortized patent costs	12,978	$ 16,336
Revenues attributable to one customer	$ 85,000

XML

Basic Loss Per Share (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Basic Loss Per Share Details
Company had stock options	11,685,852
Stock warrants outstanding to purchase shares of common stock	64,326,510
Company maintains its cash with one domestic financial institution (FDIC)	$ 443,000	$ 657,000
Before adjustments for outstanding checks and deposits in transit	$ 250,000

XML

Agreement with Desmet Ballestra (Narrative) (Details) - USD ($)	Sep. 30, 2016	Jan. 22, 2016
Agreement with Desmet Ballestra Details
Limited monthly advance payments against future sales		$ 50,000
Revenues from Desmet	$ 85,000
Desmet and received advances	100,000
Company recorded receivable from Desmet	127,500
Advance payments received	472,500
Share in gross margin	$ 317,000

XML

Property and equipment consisted of the following (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Property and equipment consisted of the following
Leasehold improvement	$ 2,475	$ 2,475
Furniture	26,837	26,837
Office equipment	1,499	1,499
Equipment	68,380	68,380
Systems	352,655	352,655
Property and equipment, gross	451,846	451,846
Less: accumulated depreciation and amortization	(337,614)	(329,205)
Property & Equipment, net	$ 114,232	$ 122,641

XML

Property, Plant and Equipment (Depreciation Expense Narrative) (Details) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Property and equipment - Depreciation expense
Depreciation expense	$ 8,409	$ 9,824

XML

Accrued Payroll and Payroll Taxes (Narrative) (Details) - USD ($)	Sep. 30, 2016	Jun. 30, 2016
Accrued Payroll And Payroll Taxes Narrative Details
Accrued salaries of officers	$ 994,033	$ 994,033

XML

Summary of the Company's Options activity (Details)	Sep. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2016 $ / shares shares
Options
Options Outstanding	11,685,352	12,595,992
Options Granted	0
Forfeited/Replaced	0
Options Exercised	0
Options Expired	0
Exercisable and vested	11,635,352
Weighted Average Exercise Price
Weighted- Average Exercise Price - Options Outstanding | $ / shares	$ 0.07	$ 0.1
Weighted- Average Exercise Price - Exercisable and vested | $ / shares	$ 0.07
Weighted- Average Remaining Contractual Life (Years)
Weighted- Average Remaining Contractual Life - Options Outstanding	5.02	4.96
Weighted- Average Remaining Contractual Life - Exercisable and vested	5.02
Intrinsic value of the outstanding options | $	$ 0

XML

Summary of additional information concerning options outstanding and exercisable (Details)	Sep. 30, 2016 $ / shares shares
Options Outstanding Number of shares
Options outstanding and exercisable with Exercise Price 0.03	11,000,000
Options outstanding and exercisable with Exercise Price 0.33	174,022
Options outstanding and exercisable with Exercise Price 0.67	511,830
Total Options outstanding and exercisable	11,685,852
Options Outstanding - Weighted Average Remaining Life (Years)
Options outstanding and exercisable with Exercise Price 0.03	5.71
Options outstanding and exercisable with Exercise Price 0.33	1.85
Options outstanding and exercisable with Exercise Price 0.67	1.75
Options Outstanding - Weighted-Average Exercise Price
Options outstanding and exercisable with Exercise Price 0.03 | $ / shares	$ 0.03
Options outstanding and exercisable with Exercise Price 0.33 | $ / shares	0.33
Options outstanding and exercisable with Exercise Price 0.67 | $ / shares	$ 0.67
Options exercisable - Number of shares
Options outstanding and exercisable with Exercise Price 0.03	11,000,000
Options outstanding and exercisable with Exercise Price 0.33	174,022
Options outstanding and exercisable with Exercise Price 0.67	511,830
Options exercisable - Weighted Average Remaining Life (Years)
Options outstanding and exercisable with Exercise Price 0.03	5.71
Options outstanding and exercisable with Exercise Price 0.33	1.85
Options outstanding and exercisable with Exercise Price 0.67	1.75

XML

Summary of the Company's warrant activity (Details)	Sep. 30, 2016 $ / shares shares	Jun. 30, 2016 $ / shares shares
Warrants
Warrants Outstanding | shares	64,326,510	64,326,510
Warrants Vested and exercisable | shares	64,326,510
Warrants - Weighted-Average Exercise Price
Outstanding Warrants Weighted-Average Exercise Price | $ / shares	$ 0.07	$ 0.07
Warrants Vested and exercisable Weighted-Average Exercise Price | $ / shares	$ 0.07
Warrants - Weighted- Average Remaining Contractual Life (Years)
Outstanding Warrants Weighted- Average Remaining Contractual Life (Years)	4.83	5.09
Warrants Vested and exercisable Weighted- Average Remaining Contractual Life (Years)	4.83

XML

Summary of additional information concerning Warrants outstanding and exercisable (Details)	3 Months Ended
	Sep. 30, 2016 $ / shares shares
Warrants Outstanding Number of shares
Warrants outstanding and exercisable with Exercise Price 0.04 - 0.07	43,999,851
Warrants outstanding and exercisable with Exercise Price 0.12	20,326,659
Total Warrants outstanding and exercisable	64,326,510
Warrants Outstanding - Weighted Average Remaining Life (Years)
Warrants outstanding and exercisable with Exercise Price 0.04 - 0.07	5.69
Warrants outstanding and exercisable with Exercise Price 0.12	3.00
Warrants Outstanding - Weighted-Average Exercise Price
Warrants outstanding and exercisable with Exercise Price 0.04 - 0.07 | $ / shares	$ 0.05
Warrants outstanding and exercisable with Exercise Price 0.12 | $ / shares	$ 0.12
Warrants exercisable - Number of shares
Warrants outstanding and exercisable with Exercise Price 0.04 - 0.07	43,999,851
Warrants outstanding and exercisable with Exercise Price 0.12	20,326,659
Total Warrants outstanding and exercisable	64,326,510
Warrants exercisable - Weighted Average Exercise Price
Warrants outstanding and exercisable with Exercise Price 0.04 - 0.07 | $ / shares	$ 0.05
Warrants outstanding and exercisable with Exercise Price 0.12	0.12

XML

Litigation (Details) - USD ($)	Jan. 31, 2016	Aug. 31, 2014
Litigation Details
A former employee and former Director filed an administrative Complaint in unpaid wages for approximately		$ 179,000
Obligation to the former employee and former Director only amounted which was amounted to approximately	$ 134,000